

Teplizumab Road Map — Stage 3

Family-facing summary of the treatment journey

WHAT IS TZIELD?

- IV medication that modifies the immune system's attack on insulin-producing cells
- Goal: preserve the beta cells still working after a Stage 3 diagnosis
- Not a cure — your child will still need insulin

BENEFITS & RISKS

- Preserves C-peptide (endogenous insulin production)
- May mean smoother blood sugars and fewer severe lows over time
- Common side effects: low WBC counts, rash, headache, flu-like symptoms, nausea
- Premedication and close monitoring reduces risk

THE INFUSION JOURNEY

- 12 consecutive days of IV infusion (×2 courses, 6 months apart)
- Infusion: ~30 minutes, ages 8–17
- Each day: premedication → labs → IV → observation
- Interval labs on days 2, 4, 6, 9, 12
- Vascular access options: daily IV, midline, or PICC

FOLLOW-UP & CARE

- 1 month: confirm labs normalize
- 3 months: diabetes management check
- 6 months: Course 2 begins (12 more days)
- 12 months and yearly: C-peptide, HbA1c, CGM review
- Vaccination timing restrictions apply

Call us right away if your child has:

Fever >101°F • Persistent vomiting • Rash with swelling or trouble breathing • Severe fatigue • Signs of infection • Abdominal pain or jaundice

Getting started

Insurance review & authorization • TZIELD COMPASS enrollment (Sanofi support: travel, education, mentorship) • We'll partner with you every step

Teplizumab preserves insulin production but does not cure diabetes. Your child will still need insulin.